Improving safety, efficiency and regulatory compliance via asset documentation integrity
Innovation series partnering & valuing oncology assets - may 2012
(PowerPoint)
Off-Label Communications and the Public Health Presentation to the Pharmaceutical Compliance Forum November 8, 2007 Paul E. Kalb, M.D., J.D. With appreciation.
© FIMM - Institiute for Molecular Medicine Finland High Throughput Biomedicine Unit (HTB) at FIMM Technology Centre.
Re-Engineering Early Phase Cancer Drug Development: Decreasing the Time from Novel Target to Novel Therapeutic
bio.11
PSM Interchange 2014 Panel 2: Linda Marks, Criminal Prosecutions: Patient Safety
Solving the operational challenges of oncology clinical trials
Oncology Drugs: The journey From Manufacturer To The End User
Cancer is Still a Major Problem
Stuart Peacock
